In November 2015 it was announced that Abcam plc would acquire AxioMx, Inc. The firm had been involved in discovery, development, production, and delivery of recombinant antibodies against the human proteome. It also offers custom recombinant antibody discovery and development services ranging from peptide synthesis to large-scale antibody production. The company's services include antigen and peptide synthesis, epitope mapping, phage display library screening and affinity maturation, and custom phage display library development; and antibody design, modification, optimization, and production. In addition, AxioMx, Inc. offers a range of custom antibody discovery and development services for the research and diagnostic market places. The company's recombinant antibodies are used in western blotting, ELISAs, flow cytometry, immunohistochemistry, and immunoprecipitation applications. Founder principals are life science entrepreneurs having previously led successful genomics, next-generation sequencing, microfluidics, bioinformatics and proteomic organizations. AxioMxâs unique platform of proprietary phage display libraries, library screening, and affinity maturation methods provides the technical foundation of the company. The company offers a full range of custom antibody discovery and development services for the research and diagnostic market places.
